Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

Liu, Wei Ping; Ji, Xinqiang; Song, Yuqin; Wang, Xiaopei; Zheng, Wen; Lin, Ningjing; Tu, Meifeng; Xie, Yun; Ping, Lingyan; Ying, Zhitao; Zhang, Chen; Deng, Lijuan; Wu, Meng; Feng, Fanchao; Leng, Xigang; Sun, Yingli; Du, Tingting; Zhu, Jun

doi:10.1002/cam4.3037

Cited by 55 publications

(55 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In China, a retrospective study included a total of 679 PTCL patients over two decades. The 5-year OS rate of 34.9% in AITL and 27.6% in PTCL, NOS were reported in this study, with no improvement of survival during the past two decades [5].…”

Section: Discussionsupporting

confidence: 47%

See 1 more Smart Citation

Chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide (C-CHOEP) regimen is superior to the GDP-ML and CHOEP regimen for patients with newly diagnosed peripheral T-cell lymphoma

Wei

Zhang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Outcomes with CHOP (cyclophosphamide, epirubicin, vindesine, and prednisone) or CHOP-like regimens are poor in most types of peripheral T-cell lymphomas (PTCLs). In this study, we investigated whether the combination of chidamide with CHOEP (cyclophosphamide, epirubicin, vindesine, etoposide, and prednisone) regimen (C-CHOEP) was superior to CHOEP and GDP-ML (gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase) regimen for previously untreated PTCL patients. Methods Between January 2012 and August 2019, a total of 94 newly diagnosed PTCL patients were included in this study, including 34 patients from the C-CHOEP phase 2 trial, 34 patients treated with CHOEP regimen matched to those in the C-CHOEP group, and 26 patients from a previous phase 2 trial of GDP-ML therapy. Results The complete remission rate of patients in the C-CHOEP group was significantly higher than that of GDP-ML and CHOEP group (55.9% vs. 32.0% and 29.4%, p = 0.047), with an overall response rate of 82.4 vs. 64.7%, and 72.0%, respectively (p = 0.244). The overall survival of patients in the C-CHOEP group was significantly superior than that of the GDP-ML and CHOEP group, with 1- and 3- year OS rates of 80.9% and 73.5% in the C-CHOEP group vs. 67.4% and 36.9% in the GDP-ML group, and 64.6% and 48.9% in the CHOEP group (p = 0.048). Progression-free survival (PFS) was also improved with median PFS of 19.8 months in the C-CHOEP group vs. 6.6 and 8.1 months in the GDP-ML and CHOEP group. The most common adverse events were hematologic toxicities. Grade 3–4 neutropenia and febrile neutropenia occurred in 58.8% and 20.6% of patients in the C-CHOEP group with no significant difference compared with the CHOEP group. Conclusion Our study suggested that C-CHOEP therapy was superior to CHOEP and GDP-ML therapy for newly diagnosed PTCL patients as shown by a significant improvement of CR rate and OS with a favorable safety profile. Trial registration: The study of C-CHOEP regimen is registered at ClinicalTrials.gov on December 2nd 2016 (NCT02987244). The study of GDP-ML regimen is registered at Chinese Clinical Trial Registry on March 30th 2012 (ChiCTR-ONC-12002055).

show abstract

Section: Discussionsupporting

confidence: 47%

“…Anthracycline-based regimens such as CHOP or CHOP-like regimens remain the most commonly used and complete remission (CR) rates of around 50% have been reported [3,4]. However, such regimens failed to induce sustained remission with a long-term survival of only 30-40% in most types of PTCLs [1,[3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide (C-CHOEP) regimen is superior to the GDP-ML and CHOEP regimen for patients with newly diagnosed peripheral T-cell lymphoma

Wei

Zhang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Autologous HSCT is the standard therapeutic modality for patients with NHL 9 - 12 . The successful mobilization of PB stem cells and adequate stem cell collection are of critical importance, as the infused CD34 + cell dose can affect the engraftment of platelet and neutrophils 13 .…”

Section: Discussionmentioning

confidence: 99%

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Targeting the interaction between SDF1 and CXCR4 may provide an opportunity to intervene in the hematopoietic stem cell mobilization process. Aim: The present study aimed to investigate the safety, efficacy, pharmacokinetic and pharmacodynamic profiles of YF-H-2015005, a CXCR4 antagonist, for the mobilization of hematopoietic stem cells (HSCs). Methods: A total of 15 patients with non-Hodgkin's lymphoma (NHL) eligible for autologous hematopoietic stem cell transplantation were enrolled. All patients achieved a partial or complete remission after the first-or second-line therapy. Granulocyte colony stimulating factor (G-CSF) was given in the morning for 8 consecutive days, and 0.24 mg/kg YF-H-2015005 was subcutaneously administered in the evening of the 4 th day of G-CSF treatment for up to four days. Apheresis was performed 9-10 hours following each dose of YF-H-2015005. Results: YF-H-2015005 was rapidly absorbed and eliminated, with Tmax and t1/2 of 0.5 and 5.04 ± 1.00 hours, respectively. Moreover, the mean peripheral blood CD34 + cell counts were elevated by 2.0-to 2.9-fold from 2 to 24 hours, and reached the maximum level of 76.5 ± 53.9 cells/kg at 10 hours after YF-H-2015005 treatment. Fourteen (93%) out of 15 NHL patients achieved a minimum target of ≥2×10 6 /kg CD34 + cells. Furthermore, there was no grades 3-4 treatment-related adverse event observed among these patients. Conclusion: YF-H-2015005 can serve as a safe, effective agent in combination with G-CSF for CD34 + hematopoietic progenitor cell mobilization in NHL patients.

show abstract

“…Extranodal NK/T cell lymphoma, nasal type (ENKTL), an aggressive lymphoma derived from NK cells or cytotoxic T cells with a strong association with Epstein Barr Virus (EBV), is prevalent in Asia including China, Central and South America [63,64]. It was well known that multiple factors such as EBV infection, immunogenetic background, defective immune surveillance, and environmental factors have been implicated in the pathogenesis of ENKTL [64][65][66][67].…”

Section: Extranodal Nk/t Cell Lymphoma Nasal Typementioning

confidence: 99%

Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

Xie

Zeng

et al. 2020

Exp Hematol Oncol

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCLs) are biologically and clinically heterogeneous diseases almost all of which are associated with poor outcomes. Recent advances in gene expression profiling that helps in diagnosis and prognostication of different subtypes and next-generation sequencing have given new insights into the pathogenesis and molecular pathway of PTCL. Here, we focus on a broader description of mutational insights into the common subtypes of PTCL including PTCL not other specified type, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, and extra-nodal NK/T cell lymphoma, nasal type, and also present an overview of new targeted therapies currently in various stages of clinical trials.

show abstract

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

Cited by 55 publications

References 30 publications

Chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide (C-CHOEP) regimen is superior to the GDP-ML and CHOEP regimen for patients with newly diagnosed peripheral T-cell lymphoma

Chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide (C-CHOEP) regimen is superior to the GDP-ML and CHOEP regimen for patients with newly diagnosed peripheral T-cell lymphoma

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients

Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

Contact Info

Product

Resources

About